A Seoul developer has won U.S. regulatory clearance for software that helps clinicians judge how quickly a patient with mild cognitive impairment may decline. NeuroXT’s NEXT-Cue secured 510(k) clearance from the FDA.
The Class II Software as a Medical Device fuses brain MRI images, demographic information and cognitive assessment data to estimate whether a patient under evaluation for MCI is likely to progress to Alzheimer’s dementia within five years. Clinical judgment and individualized management planning remain the clinician’s job; the tool is meant to supplement them, not replace them.
The clearance lands as anti-amyloid therapies make early identification more consequential. Newer drugs work best in patients at the mild stage, so a tool that flags likely progression can shape who gets worked up, monitored or referred for treatment planning.
For CEO Joon-Kyung Seong, the decision represents a landmark step as the company moves into the American market. The company plans to establish real-world clinical use cases at U.S. institutions and accelerate commercialization.
Separately, NeuroXT is pursuing authorization from Korea’s Ministry of Food and Drug Safety and expects to begin selling there early next year, an unusual sequence for a Korean imaging startup that has usually cleared at home first.
The company builds AI imaging biomarkers for Alzheimer’s disease, mostly from MRI, to characterize pathology and likely treatment response. Its broader pitch is precision medicine for timing, choosing when a patient should start therapy rather than only whether they qualify. That positioning puts it in the same queue as a growing field of neurodegeneration tools seeking Medicare-covered clinical footing in the U.S.
